2[3]Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol,2000,18(16)∶2981-2989.
3[4]Orlowski TM, Szczesny TJ. Surgical treatment of stage Ⅲ non-small cell lung cancer. Lung Cancer,2001,34(Suppl 2)∶s137-s143.
4[5]Gdeedo A, Van Schil P, Corthouts B, et al. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J,1997,10(7)∶1547-1551.
5[6]Berlangieri SU, Scott AM, Knight SR, et al. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg,1999,16(Suppl 1)∶S25-30.
6[7]Ryu JS, Choi NC, Fischman AJ, et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer,2002,35(2)∶179-187.
7[8]Albes JM, Dohmen BM, Schott U, et al. Value of positron emission tomography for lung cancer staging. Eur J Surg Oncol,2002,28(1)∶55-62.
8[9]Kalff V, Hicks RJ, MacManus MP, et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol,2001,19(1)∶111-118.
9[10]van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet,2002,359(9315)∶1388-1393.
10[11]Kirschner PA. Cervical mediastinoscopy. Chest Surg Clin N Am,1996,6(1)∶1-20.
二级参考文献16
1Eberhardt W, Wilke H, Stamatis G, et al. Preoperative chemotherapy followed byconcurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy anddefinitive surgery in locally advanced non-small cell lung cancer: mature results of aphase Ⅱ trial. J Clin Oncol,1998,16(3)∶622-634.
2Fleck J, Camargo J, Godoy D, et al. Chemoradiation therapy alone versuschemotherapy alone as a neoadjuvant treatment for stage Ⅲ non-small cell lung cancer.Proc Am Soc Clin Oncol,1993,12(2)∶333.
3Gandara DR, Leigh B, Vallieres E, et al. Preoperative chemotherapy in stage Ⅲnon-small cell lung cancer: Long-term outcome. Lung Cancer,1999,26(1)∶3-6.
4Rosell R, Gomez CJ, Camps C, et al. Preresectional chemotherapy in stage Ⅲnon-small cell lung cancer: a 7-year assessment of a randomized controlled trial. LungCancer,1999,47(1)∶7-14.
5Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolleda randomized trial comparing perioperative chemotherapy and surgery with surgery alone inresectable stage ⅢA non-small cell lung cancer. Lung Cancer,1998,21(1)∶1-6.
6Albain KS, Pass HI. Induction therapy before surgery for non-small cell lungcancer. Lung Cancer,2000,29(Suppl 2)∶168-171.
7Mattson K, Velde T, Krotta K, et al. Early results of an international phase Ⅲstudy evaluating Toxotere as neoadjuvant therapy for radically treatable stage Ⅲ NSCLC.Lung Cancer,2000,29(Suppl 1)∶90.
8Abolhoda A, Martin J, Ginsberg RJ, et al. Morbidity and modality for pulmonaryresections in lung cancer after induction treatment. Lung Cancer,2000,29(Suppl 1)∶89.
9Takamori S, Rikimaru T, Hayashi A, et al. A preoperative alternating chemotherapyand radiotherapy program for patients with stage ⅢA(N2) non-small cell lung cancer. LungCancer,2000,29(1)∶49-56.
10Strupp J, Johnson DH, Greco FA, etal. Combined treatment of small cell bronchopulmonary cancer. Results of a retrospectivestudy of 59 patients. Rev Pneumol Clin,1984,40(5)∶327-331.
3Scalan M J.Gure A O,Jungbluth A A,et al. Cancer/Testis Antigens: an Expanding Family of Targets for Cancer Immunotherapy[J].Immunol Rev, 2002,188:22-32.
4Timmons P M, Rigby P W, Poirier F. The Murine Seminiferous Epithelial Cycle is Pre-Figured in the Sertoli Cells of the Embryonic Testis[J]. Development,2002,129(3):635-647.
5Jong S C,Birmingham J M,Pai S H. Immunomodulatory Substances of Fungal Origin[J]. Journal of Immunology and Immunopharmacology,1991,11:115-122.
6Kidd P M. The Use of Mushroom Glucans and Proteoglycans in Cancer Treatment[J]. Altern Med Rev,2000,5(1):4-27.
7Borchers A T,Stern J S,Hackman R M,et al. Mushrooms, Tumors, and Immunity[J]. Proc Soc Exp Biol Med,1999,221(4):281-293.
8Hotta H,Hagiwara K,Tabata K,et al. Augmentation of Protective Immune Responses Against Sendai Virus Infection by Fungal Polysaccharide Schizophyllan[J]. Int J Immunopharmac,1993,15(1):55-56.
9Zhao C G,H Sun,Tong X,et al. An Antitumor Lectin from Edible Mushroom Agrocybe aegerita[J]. Biochem J,2003,374:321-327.
10Sun H,Zhao C G,Tong X,et al. A Lectin with Mycelia Differentiation and Antiphytovirus Activities from the Edible Mushroom Agrocybe aegerita[J]. J Biochem Mol Biol,2003,36(2):214-222.
